A user's experience with microneedling monotherapy and potential treatments such as finasteride, minoxidil, Stemoxydine, rosemary oil, peppermint oil, and RU58841 for reversing hair loss.
A gel of keratin microspheres promotes hair follicle growth, showing similar effectiveness to minoxidil in mice. The treatment activates hair growth pathways and reduces inflammation, with potential applications in drug delivery for hair-related disorders.
A user is testing clascoterone (Winlevi) on their scalp for hair loss and has noticed a reduction in scalp sebum after one month. They are also using other unspecified treatments and plan to provide an update after the second month.
SCUBE3 is available online but poses risks like tumor promotion and high costs. Users advise against using it due to health concerns and inefficacy as a standalone treatment.
The user experienced reduced hair loss using grey-market KX-826 alongside Minoxidil foam, achieving better results with Minoxidil liquid but restricted to foam due to an allergy. Initial side effects included shortness of breath, racing heart, and dizziness, which subsided after the first week.
Kintor's Pyrilutamide (KX-826) showed hair growth in Chinese Phase III trials but did not significantly outperform placebo. The treatment was safe with no major adverse reactions reported.
The conversation discusses the less impressive results of Pyrilutamide (kx-836) in phase 3 compared to phase 2, with a suggestion that a longer study might show more significant results. One user reports personal success with Pyrilutamide, experiencing no further hair loss and gradual regrowth.
Fatty acid metabolic signaling can activate epithelial stem cells for hair regeneration. Oleic and palmitoleic acids showed the best results, but practical application on humans remains uncertain.
The conversation is about using DIY copper peptide (GHK CU) serum for microneedling to address hair loss, with additional treatments including Nizoral for DHT reduction and red light therapy. The user is considering adding Minoxidil but is concerned due to having cats.
LagRag revived their hair using finasteride, minoxidil, derma rolling, dermapen, and biotin shampoo. Users discussed the effectiveness and requested photos with different hair positions.
A user is interested in Absci's AI-driven antibody platform, ABS-201, for treating androgenetic alopecia, which shows promising preclinical results and potential for hair regrowth and pigmentation restoration. However, concerns are raised about the drug's development timeline and its advantages compared to existing treatments.
PP405's phase 2a trial results were presented, focusing on safety and pharmacokinetics, with a future meeting planned to share the full dataset. The trial includes a randomized controlled portion and an open-label extension, with no indication of phase 2B completion.
The conversation discusses using USB microscopes for scalp photos and provides a link to an overview of trichoscopy. Treatments mentioned include Minoxidil, finasteride, and RU58841.
The conversation discusses whether stemoxydine needs to be used for life for hair loss treatment. One user suggests that stemoxydine does not require lifelong use and can make hair exit the resting phase faster, but the benefits may be temporary.
A user shared their 3-month progress using RU58841, 10% minoxidil, and microneedling every two weeks for hair loss. They found the new minoxidil sprayer effective for applying the treatment across the scalp.
A user warns against buying the Koreabeautics V2 microneedling pen, claiming it's marketed through fake success stories and is overpriced. Another user shares their experience, acknowledging the pen's quality but agreeing it's too expensive and reliant on frequent needle head replacements.
Microneedling with 5% minoxidil improves hair growth for hair loss patients. Best protocol: 1.5mm dermaroller weekly for 12 weeks or 0.6mm dermapen every 2 weeks for 12 weeks, skipping topicals for 24 hours.
A user experienced increased shedding after adding KX-826 to their long-term finasteride and minoxidil regimen. Another user reported mild side effects from KX-826, such as stomach and testicle pain.
Clascoterone in Winlevi, a topical AR antagonist, is being re-examined due to concerns about HPA axis suppression in adolescents, but it's unlikely to be banned for adult use in androgenetic alopecia (AGA). The European Medicines Agency recommended refusing Winlevi for acne vulgaris, but this may not affect Breezula's approval for AGA.
KX-826 combined with minoxidil significantly increases hair growth compared to minoxidil alone for treating male androgenetic alopecia, with no unexpected safety concerns. Users discuss various hair loss treatments, including KX-826, minoxidil, finasteride, and RU58841, sharing personal experiences and sourcing information.
A user shared their experience with microneedling and minoxidil for hair loss, avoiding finasteride due to concerns about systemic hormone effects. They reported slight hair regrowth after one month and plan to continue the regimen, noting improvements in skin sensitivity and managing dandruff with anti-dandruff shampoo.
The conversation is about purchasing RU58841 for hair loss treatment from Xian Lyphar BioTech. Users confirm the company is legitimate and the price is reasonable.
KX-826 Phase II results show that a 0.5% concentration performs better than 1% for treating male pattern baldness. Concerns about receptor upregulation from long-term DHT antagonism were mentioned.
A 3-month update on a microneedling-only project to treat hair loss, which has not had significant results in terms of thicker hair but may have seen some acceleration in hair growth and an increase in vellus hairs. The user plans to continue the journey for 6 months before making any changes, such as adding minoxidil or finasteride.
Methylsulfonylmethane (MSM) is not a treatment for male pattern baldness but can accelerate hair growth and thicken miniaturized hairs, with the side effect of increased hair growth all over the body. The user asks others to share their experiences with MSM.
A new hair loss treatment called TDM-105795 is discussed as a potential replacement or add-on to Minoxidil. Users express hope for new effective treatments.
Taurine shows potential in combating hair loss caused by chemical stress, especially when combined with other treatments like finasteride. Finasteride demonstrated better stress-reducing effects in the study.
The conversation discusses affordable low-level light therapy (LLLT) products for hair loss, with users debating the effectiveness of red LEDs versus lasers. The original poster is already using finasteride, minoxidil, ketoconazole, and microneedling, and is seeking budget-friendly LLLT options to add to their regimen.
A user created a free AI-powered hair transplant simulator to help visualize post-transplant results, seeking feedback and offering it as a tool for clinics. Users discussed its usefulness, limitations, and the requirement for email and phone verification to prevent abuse.
Replicel's results were delayed, but Shiseido might share data at BioJapan on October 11. Users are hopeful for new treatments like RCH-01, potentially eliminating the need for finasteride or minoxidil.